A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Mild to Moderate AD
Latest Information Update: 13 Dec 2024
At a glance
- Drugs Tertomotide (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Adverse reactions; Therapeutic Use
- Sponsors GemVax & KAEL
Most Recent Events
- 09 Dec 2024 According to a GemVax & KAEL media release, a Phase 2 Alzheimers disease clinical trial of GV1001 is currently ongoing in the U.S. and Europe (NCT05189210).
- 11 Apr 2024 Planned primary completion date changed from 16 Sep 2025 to 19 Apr 2025.
- 07 Mar 2024 Planned End Date changed from 30 Sep 2024 to 10 Mar 2026.